Merck divests Biosimilars business to Fresenius
- Details
- Category: Merck Group
Merck, a leading science and technology company, has announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with Merck’s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines.
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
- Details
- Category: Novartis
Novartis today announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials[1],[2].
Pfizer unveils ATLAS®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries
- Details
- Category: Pfizer
Pfizer Inc. today announced the launch of the company's Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries.
Merck partners with University of California, San Diego (UCSD) to fight Neglected Tropical Diseases
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced that it has agreed with the University of California, San Diego (UCSD) to share compounds under the WIPO Re:Search open innovation umbrella, thereby deepening its efforts in the fight against Neglected Tropical Diseases (NTDs) to identify potential cures for leishmaniasis, Chagas disease (American trypanosomiasis) and human African trypanosomiasis (HAT, sleeping sickness).
Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston.
Novartis expands development programs for NASH through clinical collaboration with Allergan
- Details
- Category: Novartis
Novartis announced today that it has entered into a clinical trial agreement with Allergan plc to conduct a Phase IIb study, involving the combination of a Novartis FXR agonist and Allergan's cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH). The financial details of this transaction are not disclosed.
Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to Biogen (NASDAQ:BIIB), and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy (DMD), to Roche.
More Pharma News ...
- PatientsLikeMe and Shire Pharmaceuticals collaborate to study rare genetic diseases
- Health risk assessments shed light on early predictors of depression
- Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer
- Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
- First collaborative definition of patient centricity
- Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
- Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment